Discussion
Patient advocates are preparing for the potential withdrawal of Tavneos (avacopan) for ANCA-associated vasculitis (AAV) in the U.K. as regulators there and in the U.S. weigh whether to pull the plug on the therapy’s approval. Authorities in the European Union have…